Skip to main content
Top
Published in: Internal and Emergency Medicine 8/2017

01-12-2017 | Points of View

The involvement of pharmacies in the screening of undiagnosed atrial fibrillation

Authors: Pietro Amedeo Modesti, Gianni Donigaglia, Plinio Fabiani, Nicola Mumoli, Andrea Colella, Maria Boddi

Published in: Internal and Emergency Medicine | Issue 8/2017

Login to get access

Abstract

Early identification of atrial fibrillation (AF) is now a priority in cardiovascular prevention because AF is common although often asymptomatic, and is associated with poor outcomes that are highly preventable with appropriate medical treatment. In Italy, AF prevalence among subjects aged ≥65 years ranges from 5 to 6% in observational studies based on the diagnosis recorded by general practitioners to 10–11% in studies where ECG screening is routinely offered. It is thus evident that a large number of subjects are not detected by conventional approach, and new strategies are required to increase early detection of AF. In particular, the changing position of pharmacies in the health system should be considered. Because of its small geographical size, insular nature and captive population, the Isle of Elba represents an ideal setting to test new strategies for stroke reduction. The Elba-FA project was thus designed to determine the feasibility and impact of the combined involvement of pharmacies and general practices to screen undiagnosed AF, with the ultimate aim of reducing the burden of stroke and arterial thromboembolism. The findings obtained with this approach might have broad implications for cardiovascular prevention at the general population level in Italy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146(12):857–867CrossRefPubMed Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146(12):857–867CrossRefPubMed
2.
go back to reference Di Minno MN, Russolillo A, Di Minno A, Camera M, Parolari A, Tremoli E (2013) Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. Expert Opin Emerg Drugs 18(1):9–23. doi:10.1517/14728214.2013.777427 CrossRefPubMed Di Minno MN, Russolillo A, Di Minno A, Camera M, Parolari A, Tremoli E (2013) Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. Expert Opin Emerg Drugs 18(1):9–23. doi:10.​1517/​14728214.​2013.​777427 CrossRefPubMed
3.
go back to reference Prisco D, Ageno W, Becattini C, D’Angelo A, Davi G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med. doi:10.1007/s11739-017-1628-6 Prisco D, Ageno W, Becattini C, D’Angelo A, Davi G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med. doi:10.​1007/​s11739-017-1628-6
4.
5.
go back to reference Coleman CI, Antz M (2017) Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). Intern Emerg Med. doi:10.1007/s11739-017-1624-x Coleman CI, Antz M (2017) Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). Intern Emerg Med. doi:10.​1007/​s11739-017-1624-x
6.
go back to reference Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Kober L, Gislason GH, Torp-Pedersen C, Fosbol EL (2015) Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace 17(2):187–193. doi:10.1093/europace/euu225 CrossRefPubMed Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Kober L, Gislason GH, Torp-Pedersen C, Fosbol EL (2015) Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace 17(2):187–193. doi:10.​1093/​europace/​euu225 CrossRefPubMed
7.
go back to reference Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962. doi:10.1093/eurheartj/ehw210 CrossRefPubMed Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962. doi:10.​1093/​eurheartj/​ehw210 CrossRefPubMed
8.
go back to reference Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V (2015) Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 14(4):377–387. doi:10.1016/s1474-4422(15)70027-x CrossRefPubMed Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V (2015) Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 14(4):377–387. doi:10.​1016/​s1474-4422(15)70027-x CrossRefPubMed
9.
go back to reference Salvatori V, Becattini C, Laureti S, Baglioni G, Germini F, Grilli P, Guercini F, Filippucci E, Agnelli G (2015) Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. Intern Emerg Med 10(5):595–601. doi:10.1007/s11739-015-1241-5 CrossRefPubMed Salvatori V, Becattini C, Laureti S, Baglioni G, Germini F, Grilli P, Guercini F, Filippucci E, Agnelli G (2015) Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. Intern Emerg Med 10(5):595–601. doi:10.​1007/​s11739-015-1241-5 CrossRefPubMed
11.
go back to reference Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GYH, G-A Investigators (2016) Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace 18(9):1308–1318. doi:10.1093/europace/euw073 CrossRefPubMedPubMedCentral Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GYH, G-A Investigators (2016) Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace 18(9):1308–1318. doi:10.​1093/​europace/​euw073 CrossRefPubMedPubMedCentral
12.
go back to reference Savelieva I, Camm AJ (2000) Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 4(2):369–382CrossRefPubMed Savelieva I, Camm AJ (2000) Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 4(2):369–382CrossRefPubMed
16.
17.
go back to reference Zoni-Berisso M, Filippi A, Landolina M, Brignoli O, D’Ambrosio G, Maglia G, Grimaldi M, Ermini G (2013) Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] Study). Am J Cardiol 111(5):705–711. doi:10.1016/j.amjcard.2012.11.026 CrossRefPubMed Zoni-Berisso M, Filippi A, Landolina M, Brignoli O, D’Ambrosio G, Maglia G, Grimaldi M, Ermini G (2013) Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] Study). Am J Cardiol 111(5):705–711. doi:10.​1016/​j.​amjcard.​2012.​11.​026 CrossRefPubMed
19.
20.
22.
go back to reference Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G (2011) Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 171(16):1441–1453. doi:10.1001/archinternmed.2011.399 CrossRefPubMed Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G (2011) Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 171(16):1441–1453. doi:10.​1001/​archinternmed.​2011.​399 CrossRefPubMed
26.
go back to reference Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, Bennett AA, Briffa T, Bauman A, Martinez C, Wallenhorst C, Lau JK, Brieger DB, Sy RW, Freedman SB (2014) Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 111(6):1167–1176. doi:10.1160/th14-03-0231 CrossRefPubMed Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, Bennett AA, Briffa T, Bauman A, Martinez C, Wallenhorst C, Lau JK, Brieger DB, Sy RW, Freedman SB (2014) Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 111(6):1167–1176. doi:10.​1160/​th14-03-0231 CrossRefPubMed
27.
29.
go back to reference Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, Breithardt G, Kirchhof P (2009) Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 11(10):1362–1368. doi:10.1093/europace/eup262 CrossRefPubMed Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, Breithardt G, Kirchhof P (2009) Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 11(10):1362–1368. doi:10.​1093/​europace/​eup262 CrossRefPubMed
30.
go back to reference Claes N, Van Laethem C, Goethals M, Goethals P, Mairesse G, Schwagten B, Nuyens D, Schrooten W, Vijgen J (2012) Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol 67(3):273–278. doi:10.2143/ac.67.3.2160714 CrossRefPubMed Claes N, Van Laethem C, Goethals M, Goethals P, Mairesse G, Schwagten B, Nuyens D, Schrooten W, Vijgen J (2012) Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol 67(3):273–278. doi:10.​2143/​ac.​67.​3.​2160714 CrossRefPubMed
31.
go back to reference Samol A, Masin M, Gellner R, Otte B, Pavenstadt HJ, Ringelstein EB, Reinecke H, Waltenberger J, Kirchhof P (2013) Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 15(5):657–662. doi:10.1093/europace/eus366 CrossRefPubMed Samol A, Masin M, Gellner R, Otte B, Pavenstadt HJ, Ringelstein EB, Reinecke H, Waltenberger J, Kirchhof P (2013) Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 15(5):657–662. doi:10.​1093/​europace/​eus366 CrossRefPubMed
33.
go back to reference Costantino G, Podda GM, Falsetti L, Iannone P, Lages A, Marra AM, Masala M, Reiakvam OM, Savva F, Schovanek J, van Bree S, da Silva Chora IJ, Privitera G, Ragozzino S, von Rotz M, Woittiez L, Davidson C, Montano N (2016) Guidelines on the management of atrial fibrillation in the emergency department: a critical appraisal. Intern Emerg Med. doi:10.1007/s11739-016-1580-x Costantino G, Podda GM, Falsetti L, Iannone P, Lages A, Marra AM, Masala M, Reiakvam OM, Savva F, Schovanek J, van Bree S, da Silva Chora IJ, Privitera G, Ragozzino S, von Rotz M, Woittiez L, Davidson C, Montano N (2016) Guidelines on the management of atrial fibrillation in the emergency department: a critical appraisal. Intern Emerg Med. doi:10.​1007/​s11739-016-1580-x
34.
go back to reference Cooke G, Doust J, Sanders S (2006) Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract 55(2):130–134PubMed Cooke G, Doust J, Sanders S (2006) Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract 55(2):130–134PubMed
38.
go back to reference Jacobs MS, Kaasenbrood F, Postma MJ, van Hulst M, Tieleman RG (2016) Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. doi:10.1093/europace/euw285 PubMed Jacobs MS, Kaasenbrood F, Postma MJ, van Hulst M, Tieleman RG (2016) Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. doi:10.​1093/​europace/​euw285 PubMed
39.
41.
go back to reference Joseph AE, Phillips DR (1984) Accessibility and utilization: geographical perspectives on health care delivery. Harper & Row Ltd, London Joseph AE, Phillips DR (1984) Accessibility and utilization: geographical perspectives on health care delivery. Harper & Row Ltd, London
42.
go back to reference Sciacqua A, Perticone M, Tripepi G, Tassone EJ, Cimellaro A, Mazzaferro D, Sesti G, Perticone F (2015) CHADS2 and CHA2DS2-VASc scores are independently associated with incident atrial fibrillation: the Catanzaro Atrial Fibrillation Project. Intern Emerg Med 10(7):815–821. doi:10.1007/s11739-015-1243-3 CrossRefPubMed Sciacqua A, Perticone M, Tripepi G, Tassone EJ, Cimellaro A, Mazzaferro D, Sesti G, Perticone F (2015) CHADS2 and CHA2DS2-VASc scores are independently associated with incident atrial fibrillation: the Catanzaro Atrial Fibrillation Project. Intern Emerg Med 10(7):815–821. doi:10.​1007/​s11739-015-1243-3 CrossRefPubMed
Metadata
Title
The involvement of pharmacies in the screening of undiagnosed atrial fibrillation
Authors
Pietro Amedeo Modesti
Gianni Donigaglia
Plinio Fabiani
Nicola Mumoli
Andrea Colella
Maria Boddi
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 8/2017
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-017-1752-3

Other articles of this Issue 8/2017

Internal and Emergency Medicine 8/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.